成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Apoptosis
  3. Apoptosis
  4. Ligustrazine

Ligustrazine  (Synonyms: 川芎嗪; Chuanxiongzine; Tetramethylpyrazine)

目錄號: HY-N0264 純度: 99.96%
COA 產(chǎn)品使用指南 技術(shù)支持

Ligustrazine (Chuanxiongzine) 是從Ligusticum chuanxiong Hort. (Chuan Xiong)中提取的一種烷基吡嗪，常在薯條、面包、茶、乳制品、豆制品等食物中作為香精。Ligustrazine 對大鼠具有潛在的抗神經(jīng)和抗炎活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Ligustrazine Chemical Structure

Ligustrazine Chemical Structure

CAS No. : 1124-11-4

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥354
In-stock
50 mg ￥322
In-stock
100 mg ￥500
In-stock
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Ligustrazine:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Ligustrazine (Chuanxiongzine), an alkylpyrazine isolated from Ligusticum chuanxiong Hort. (Chuan Xiong)[1], is present in french fries, bread, cooked meats, tea, cocoa, coffee, beer, spirits, peanuts, filberts, dairy products and soy products as fragrance and flavouring ingredienexhibits. Ligustrazine also has potential nootropic and anti-inflammatory activities in rats[2][3].

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 200 μM
Compound: 1
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
[PMID: 26891099]
A549 IC50
> 200 μM
Compound: 1
Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry
Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry
[PMID: 26891099]
A549 IC50
15.22 μM
Compound: 2
Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay
[PMID: 29424539]
A549 IC50
36.46 μM
Compound: TMP
Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
[PMID: 34186178]
A549/CDDP IC50
> 200 μM
Compound: 1
Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay
Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay
[PMID: 26891099]
A549/CDDP IC50
> 200 μM
Compound: 1
Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry
Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry
[PMID: 26891099]
Bel-7402 IC50
> 20 μM
Compound: Ligustrazine
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
[PMID: 29432947]
EA.hy 926 EC50
83.4 μM
Compound: Ligustrazine, TMP
Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay
Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay
10.1039/C4MD00022F
ECV-304 EC50
0.6 mM
Compound: TMP, Ligustrazine
Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay
Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay
10.1039/C3MD20352B
ECV-304 EC50
0.6 mM
Compound: TMP, tetramethyl pyrazine
Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay
Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay
[PMID: 21993151]
ECV-304 EC50
154.35 μM
Compound: Lig, Ligustrazine
Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs
Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs
[PMID: 19329327]
ECV-304 EC50
549 μM
Compound: Ligustrazine
Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay
Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay
[PMID: 29432947]
HBMEC-2 EC50
15.18 μM
Compound: TMP
Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
[PMID: 31541868]
HCT-116 IC50
8.17 μM
Compound: 2
Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay
[PMID: 29424539]
HeLa IC50
> 20 μM
Compound: Ligustrazine
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
[PMID: 29432947]
HepG2 IC50
> 20 μM
Compound: Ligustrazine
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 29432947]
HepG2 IC50
38.25 μM
Compound: TMP
Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
[PMID: 34186178]
HT-29 IC50
> 20 μM
Compound: Ligustrazine
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 29432947]
HUVEC EC50
788 μM
Compound: Ligustrazine
Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs
Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs
[PMID: 29432947]
K562 IC50
5.09 μM
Compound: 2
Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay
[PMID: 29424539]
MCF7 IC50
> 20 μM
Compound: Ligustrazine
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 29432947]
MCF7 IC50
29.85 μM
Compound: TMP
Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
[PMID: 34186178]
MDA-MB-231 IC50
20.44 μM
Compound: TMP
Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
[PMID: 34186178]
PC-12 EC50
64.46 μM
Compound: Ligustrazine
Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay
Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay
[PMID: 29432947]
Platelet IC50
265.3 μM
Compound: Ligustrazine, TMP
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry
10.1039/C4MD00022F
SH-SY5Y EC50
17.59 μM
Compound: TMP
Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
[PMID: 31541868]
U-87MG ATCC IC50
16.15 μM
Compound: 2
Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay
Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay
[PMID: 29424539]
體外研究
(In Vitro)

Ligustrazine 在我國廣泛用于心腦血管疾病已有近40年的歷史。由于其在多系統(tǒng)中的有效性，尤其是在心血管方面。Ligustrazine 也被用于冠心病、糖尿病、癌癥、肝損傷等多種疾病[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量

136.19

Formula

C8H12N2
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

川芎嗪
結(jié)構(gòu)分類
初始來源
運輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細(xì)胞實驗： 

DMSO 中的溶解度 : 50 mg/mL (367.13 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 7.3427 mL 36.7134 mL 73.4268 mL
5 mM 1.4685 mL 7.3427 mL 14.6854 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗：

請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (18.36 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (18.36 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑： 0.5% CMC-Na/0.5% Tween-80 in Saline water

    Solubility: 15.92 mg/mL (116.90 mM); 懸濁液; 超聲助溶

動物溶解方案計算器
請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

只
由于實驗過程有損耗，建議您多配一只動物的量
請輸入您的動物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
計算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.96%

參考文獻(xiàn)

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 7.3427 mL 36.7134 mL 73.4268 mL 183.5671 mL
5 mM 1.4685 mL 7.3427 mL 14.6854 mL 36.7134 mL
10 mM 0.7343 mL 3.6713 mL 7.3427 mL 18.3567 mL
15 mM 0.4895 mL 2.4476 mL 4.8951 mL 12.2378 mL
20 mM 0.3671 mL 1.8357 mL 3.6713 mL 9.1784 mL
25 mM 0.2937 mL 1.4685 mL 2.9371 mL 7.3427 mL
30 mM 0.2448 mL 1.2238 mL 2.4476 mL 6.1189 mL
40 mM 0.1836 mL 0.9178 mL 1.8357 mL 4.5892 mL
50 mM 0.1469 mL 0.7343 mL 1.4685 mL 3.6713 mL
60 mM 0.1224 mL 0.6119 mL 1.2238 mL 3.0595 mL
80 mM 0.0918 mL 0.4589 mL 0.9178 mL 2.2946 mL
100 mM 0.0734 mL 0.3671 mL 0.7343 mL 1.8357 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Ligustrazine
目錄號：
HY-N0264
需求量：